[Variable presentation of giant cell arteritis]
E Brouwer1,2, J van der Laken3, K Visser4
1UMC Groningen, afd. Reumatologie en Klinische Immunologie, Groningen.
Insights
Giant cell arteritis (GCA) is a rare condition affecting those over 50, potentially causing blindness. Prompt diagnosis and treatment are crucial to prevent permanent vision loss.
Area of Science:
- Rheumatology
- Ophthalmology
- Vascular Medicine
Background:
- Giant cell arteritis (GCA) is a vasculitis affecting large arteries, primarily the aorta and its branches.
- It predominantly impacts individuals over 50 years old and can lead to severe complications like irreversible blindness if not treated promptly.
- The varied clinical presentation of GCA often complicates early diagnosis.
Observation:
- This case series highlights diagnostic challenges in recognizing GCA early.
- It examines the utility and potential delays associated with fast-track clinics for suspected GCA patients.
- The presentation of two patients with GCA underscores dilemmas in initial management.
Findings:
- Variable patient presentations can delay the recognition of giant cell arteritis.
- Timely referral (within 24 hours) to specialized centers with vascular imaging is recommended.
- Early initiation of prednisolone-sparing agents alongside corticosteroids is a key consideration.
Implications:
- Improved diagnostic pathways and timely interventions are essential for preventing vision loss in GCA.
- Fast-track clinics show promise but require optimized protocols for efficient patient management.
- Further research into optimal treatment strategies, including early steroid-sparing drug use, is warranted to improve patient outcomes.
Abstract:
Giant cell arteritis is a rare disease that can lead to blindness in people older than 50 years. Early recognition and timely treatment can prevent irreversible damage. Early recognition can be challenging due to the variable presentation of giant cell arteritis. Patients suspected of having giant cell arteritis should be referred within 24 hours to a hospital that ideally has a fast-track clinic, including vascular imaging. Here we present two patients with giant cell arteritis that reflect a number of dilemmas regarding early recognition and treatment, the fast-track clinic and the early start of prednisolone-sparing drugs in giant cell arteritis.
